Cover Image
市場調查報告書

異位性皮膚炎 (AD) :流行病學預測

Atopic Dermatitis (AD) - Epidemiology Forecast to 2027

出版商 DelveInsight Business Research LLP 商品編碼 565330
出版日期 內容資訊 英文 50 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
異位性皮膚炎 (AD) :流行病學預測 Atopic Dermatitis (AD) - Epidemiology Forecast to 2027
出版日期: 2018年03月01日 內容資訊: 英文 50 Pages
簡介

本報告提供美國,EU5個國家 (德國,西班牙,義大利,法國,英國) 、日本的異位性皮膚炎 (AD) 治療藥市場相關調查分析,提供疾病概要,流行病學 (實際成果·預測) 相關的系統性資訊。

第1章 報告概要

第2章 異位性皮膚炎 (AD) 流行病學概要

  • 病患人口

第3章 疾病的背景和概要

  • 病因
  • 危險因素
  • 病理生理學
  • 異位性皮膚炎 (AD)

第4章 流行病學和患者人口

  • 疾病定義
  • 人口與預測參數
  • 人口的測量手法
  • 主要7個國家
  • 美國
  • 德國
  • 法國
  • 義大利
  • 西班牙
  • 主要7個國家的重症度別
  • 主要7個國家 (兒童)的重症度別
  • 主要7個國家 (成人)的重症度別
  • 主要7個國家的發癢的程度
  • 中症∼重病的發癢的程度
  • 主要7個國家的未治療
  • 主要7個國家的未治療 (兒童·成人)

第5章 治療行為

第6章 治療流程

  • 治療目標
  • 治療指南 (美國)
  • 指南 (日本)
  • 治療的指南 (歐洲)

第7章 目前未滿足需求

第8章 附錄

第9章 調查手法

第10章 DelveInsight的功能

第11章 免責聲明

第12章 關於DelveInsight

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DIEI0256

DelveInsight's 'Atopic Dermatitis - Epidemiology Forecast to 2027' report delivers an in-depth understanding of the disease, historical & forecasted epidemiology of Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan.

Geography Covered:

  • The United States
  • EU5 (Germany, France, Italy, Spain and the United Kingdom)
  • Japan

Study Period: 2016-2027

Atopic Dermatitis Epidemiology:

The Atopic Dermatitis (AD) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. The epidemiology data for Atopic Dermatitis are studied through all possible division to give a better understanding about the Disease scenario in 7MM. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Atopic Dermatitis Epidemiology Segmentation:

The disease epidemiology covered in the report provides historical as well as forecasted epidemiology, scenario of Atopic Dermatitis (AD) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.

The disease epidemiology covered in the report is segmented by prevalent population of Atopic Dermatitis, Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2016-2027.

According to DelveInsight, the prevalent population of Atopic Dermatitis was estimated to be 40.78 Million [7MM] in 2016 and, is expected to increase at a CAGR of XX% during the study period i.e., 2016-2027. United States accounts for the highest AD Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Adults are largely affected with the atopic dermatitis Among EU5, France has been reported to have the highest prevalent population of atopic dermatitis.

Report Scope:

  • The report covers detailed overview of Atopic Dermatitis explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The report provides the insight about the historical and forecasted patient pool of Atopic Dermatitis in 7 major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan
  • The Report assesses the disease risk and burden and highlights the unmet needs of the disease
  • The Report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report provides the segmentation of the disease epidemiology by Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults] in 7MM

Key strengths:

  • 10 Year Forecast of Atopic Dermatitis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Atopic Dermatitis
  • Prevalent Cases according to segmentation: by Severity [Children & Adults], Pruritus burden, Pruritus Severity [Moderate to Severe], Uncontrolled Atopic Dermatitis [Children & Adults]

Key assessments:

  • Patient Segmentation
  • Disease Risk & Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Report Introduction

2. Atopic Dermatitis Epidemiology Overview at a Glance

  • 2.1. Prevalent Population of Atopic Dermatitis in 2017
  • 2.2. Prevalent Populationof Atopic Dermatitis in 2027

3. Disease Background and Overview

  • 3.1. Etiology
  • 3.2. Risk Factors
  • 3.3. Pathophysiology
  • 3.4. Atopic Dermatitis
    • 3.4.1. Pruritus Associated with Atopic Dermatitis
    • 3.4.2. Diagnosis

4. Epidemiology and Patient Population

  • 4.1. Disease Definition
  • 4.2. Population and Forecast Parameters
  • 4.3. Population Methods
    • 4.3.1. Total prevalent cases in US
    • 4.3.2. EU5
    • 4.3.3. Japan
  • 4.4. Prevalent Population of Atopic Dermatitis in 7MM
  • 4.5. Prevalent Population of Atopic Dermatitis in United States
  • 4.6. Prevalent Population of Atopic Dermatitis in Germany
  • 4.7. Prevalent Population of Atopic Dermatitis in France
  • 4.8. Prevalent Population of Atopic Dermatitis in Italy
  • 4.9. Prevalent Population of Atopic Dermatitis in Spain
  • 4.10. Prevalent Population of Atopic Dermatitis in United Kingdom
  • 4.11. Prevalent Population of Atopic Dermatitis in Japan
  • 4.12. Prevalent Population of Atopic Dermatitis by Severity in 7MM
  • 4.13. Prevalent Population of Atopic Dermatitis by Severity in Children in 7MM
  • 4.14. Prevalent Population of Atopic Dermatitis by Severity in Adults in 7MM
  • 4.15. Prevalent Cases of Atopic Dermatitis by Pruritus Burden in 7MM
  • 4.16. Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases
  • 4.17. Prevalent Cases with Uncontrolled Atopic Dermatitis in 7MM
  • 4.18. Prevalent Cases with Uncontrolled Atopic Dermatitis in Children and Adults in 7MM

5. Treatment Practices

6. Treatment Algorithm

  • 6.1. Treatment Goals
  • 6.2. Treatment Guidelines by American Academy of Dermatology
  • 6.3. Japanese Guidelines for Atopic Dermatitis 2017
  • 6.4. Guidelines on the Treatment of Atopic Eczema (Atopic Dermatitis): European Dermatology Forum

7. Current Unmet Need

8. Appendix

9. Report Methodology

  • 9.1. Source Used

10. DelevInsight Capabilities

11. Disclaimer

12. About DelveInsight

List of Tables

  • Table 1: Targets focused by companies
  • Table 2: Concept of Atopic Dermatitis by Wise and Sulzberger
  • Table 3: Hanifin and Rajka Diagnostic Criteria
  • Table 4: United Kingdom Working Party diagnostic criteria
  • Table 5: American Academy of Dermatology Diagnostic Criteria
  • Table 6: Japanese Dermatological Association Diagnostic Criteria
  • Table 7: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
  • Table 8: Prevalent Population of Atopic Dermatitis in United States (2016-2027)
  • Table 9: Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
  • Table 10: Prevalent Population of Atopic Dermatitis in France (2016-2027)
  • Table 11: Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
  • Table 12: Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
  • Table 13: Prevalent Population of Atopic Dermatitis in United Kingdom (2016-2027)
  • Table 14: Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
  • Table 15: Prevalent Cases of Atopic Dermatitis by Severity in 7MM
  • Table 16: Prevalent Cases of Atopic Dermatitis by Severity in Children in 7MM
  • Table 17: Prevalent Cases of Atopic Dermatitis by Severity in Adult in 7MM
  • Table 18: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
  • Table 19: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
  • Table 20: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
  • Table 21:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
  • Table 22: Topical corticosteroids used for the treatment of Atopic Dermatitis
  • Table 23: Topical Calcineurin Inhibitors (TCIs)
  • Table 24: Topical Phosphodiesterase Type-4 (PDE4) inhibitors
  • Table 25: Oral Corticosteroids
  • Table 26: Biologic medications
  • Table 27: Non-approved systemic immunomodulating agents
  • Table 28: Reasons for noncompliance with medication

List of Figures

  • Figure 1: Risk Factors for Atopic Dermatitis
  • Figure 2: Summary of pathogenic mechanisms in acute and chronic atopic dermatitis (AD)
  • Figure 3: Pathophysiology of Pruritus in Atopic Dermatitis
  • Figure 4: Mediators involved in Pathophysiology of Pruritus in Atopic Dermatitis
  • Figure 5: Total Prevalent Population of Atopic Dermatitis in 7 MM (2016-2027)
  • Figure 6: Total Prevalent Population of Atopic Dermatitis in United States (2016-2027)
  • Figure 7: Total Prevalent Population of Atopic Dermatitis in Germany (2016-2027)
  • Figure 8: Total Prevalent Population of Atopic Dermatitis in France (2016-2027)
  • Figure 9: Total Prevalent Population of Atopic Dermatitis in Italy (2016-2027)
  • Figure 10: Total Prevalent Population of Atopic Dermatitis in Spain (2016-2027)
  • Figure 11: Total Prevalent Population of Atopic Dermatitis in the United Kingdom (2016-2027)
  • Figure 12: Total Prevalent Population of Atopic Dermatitis in Japan (2016-2027)
  • Figure 13: Total Prevalent Population of Atopic Dermatitis by Severity in 7 MM (2016-2027)
  • Figure 14: Total Prevalent Population of Atopic Dermatitis by Severity in Children in 7 MM (2016-2027)
  • Figure 15: Total Prevalent Population of Atopic Dermatitis by Severity in Adult in 7 MM (2016-2027)
  • Figure 16: Total Prevalent Population of Atopic Dermatitis by Pruritus Burden in 7 MM (2016-2027)
  • Figure 17: Prevalent Cases of Atopic Dermatitis by Pruritus Severity in Moderate to Severe Cases in 7MM (2016-2027)
  • Figure 18: Total Prevalent Population with Uncontrolled Atopic Dermatitis in 7 MM (2016-2027)
  • Figure 19:Total Prevalent Population with Uncontrolled Atopic Dermatitis in Children and Adults in 7 MM (2016-2027)
  • Figure 20: General Treatment for Atopic Dermatitis
  • Figure 21: First Line and second line treatment of Atopic Dermatitis
  • Figure 22: Current stepped treatment options for Atopic dermatitis
  • Figure 23: Current Unmet Need for Atopic Dermatitis
Back to Top